» Articles » PMID: 36467086

Bushen Huoxue Decoction Inhibits RANKL-stimulated Osteoclastogenesis and Glucocorticoid-induced Bone Loss by Modulating the NF-κB, ERK, and JNK Signaling Pathways

Overview
Journal Front Pharmacol
Date 2022 Dec 5
PMID 36467086
Authors
Affiliations
Soon will be listed here.
Abstract

Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, which is caused by a disorder in bone metabolism due to excessive activation of osteoclasts. Bushen Huoxue decoction (BHD) is an herbal formula with multiple pharmacological effects, including anti-inflammatory, antioxidant activity and stem cell migration promotion. However, the effect of BHD on osteoclastogenesis has not been reported. In this study, we aimed to elucidate the effect of BHD on RANKL-stimulated osteoclastogenesis and explored its underlying mechanisms of action . Our results show that BHD had no effect on BMMs and RAW264.7 cells viability, but inhibited RANKL-induced osteoclast formation . Furthermore, BHD attenuated RANKL-induced NF-κB, ERK, and JNK signaling. The attenuation of NF-κB, ERK, and JNK activation were enough to impede downstream expression of c-fos and NFATc1 and related specific genes. Meanwhile, we investigated the therapeutic effect of BHD on glucocorticoid-induced osteoporosis (GIOP) mice. The result indicated that BHD prevents glucocorticoid-induced osteoporosis and preserves bone volume by repressing osteoclast activity. Collectively, BHD shows significant osteoclast inhibition and holds great promise in the treatment of osteoporosis.

Citing Articles

Determination of the Combined Effects of Asian Herbal Medicine with Calcium and/or Vitamin D Supplements on Bone Mineral Density in Primary Osteoporosis: A Systematic Review and Meta-Analysis.

Park H, Kim M, Yoo Y, Lee B, Choi Y, Son C Osteoporos Int. 2024; 35(7):1-21.

PMID: 38472336 PMC: 11652406. DOI: 10.1007/s00198-024-07061-0.


capsules reduce bone loss in the subchondral bone of rats with comorbid osteoporosis and osteoarthritis by regulating metabolite alterations.

Liang G, Zhao J, Zhao D, Dou Y, Huang H, Yang W Front Med (Lausanne). 2023; 10:1256238.

PMID: 37915330 PMC: 10616798. DOI: 10.3389/fmed.2023.1256238.


Mechanisms of action and synergetic formulas of plant-based natural compounds from traditional Chinese medicine for managing osteoporosis: a literature review.

Zhou C, Shen S, Zhang M, Luo H, Zhang Y, Wu C Front Med (Lausanne). 2023; 10:1235081.

PMID: 37700771 PMC: 10493415. DOI: 10.3389/fmed.2023.1235081.

References
1.
Levin V, Jiang X, Kagan R . Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 2018; 29(5):1049-1055. DOI: 10.1007/s00198-018-4414-z. View

2.
Lee K, Chung Y, Ahn H, Kim H, Rho J, Jeong D . Selective Regulation of MAPK Signaling Mediates RANKL-dependent Osteoclast Differentiation. Int J Biol Sci. 2016; 12(2):235-45. PMC: 4737679. DOI: 10.7150/ijbs.13814. View

3.
Overman R, Yeh J, Deal C . Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2012; 65(2):294-8. DOI: 10.1002/acr.21796. View

4.
Chotiyarnwong P, McCloskey E . Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020; 16(8):437-447. DOI: 10.1038/s41574-020-0341-0. View

5.
Dovio A, Perazzolo L, Saba L, Termine A, Capobianco M, Bertolotto A . High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur J Endocrinol. 2006; 154(5):745-51. DOI: 10.1530/eje.1.02147. View